Spontaneous Preterm Birth in African-American and Caucasian Women Receiving 17α-Hydroxyprogesterone Caproate

被引:17
|
作者
Timofeev, Julia [1 ]
Singh, Jasbir [1 ]
Istwan, Niki [2 ]
Rhea, Debbie [2 ]
Driggers, Rita W. [1 ]
机构
[1] MedStar Washington Hosp Ctr, Dept Obstet & Gynecol, Washington, DC USA
[2] Alere Hlth, Dept Clin Res, Womens & Childrens Hlth, Atlanta, GA USA
关键词
preterm birth; 17-hydroxyprogesterone caproate; racial disparity; GESTATIONAL-AGE; RISK-FACTORS; WEIGHT;
D O I
10.1055/s-0033-1334452
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
ObjectiveTo determine if the rates of recurrent spontaneous preterm birth in women receiving 17-hydroxyprogesterone caproate (17P) differ according to maternal race. Study DesignRetrospective analysis of a cohort of women enrolled in outpatient 17P administration at<27 weeks. Maternal characteristics, obstetric history, and rates of recurrent preterm birth were determined using chi-square and multivariable Cox proportional hazards regression at two-tailed =0.05. Primary study outcome was defined as having a spontaneous preterm birth<34 weeks. ResultsAfrican-American women initiated 17P injections later (19.6 versus 18.9 weeks, p<0.001) and discontinued injections earlier (33.2 versus 34.1 weeks, p<0.001) than Caucasian women. Spontaneous recurrent preterm birth<34 weeks was higher in African-Americans versus Caucasians receiving 17P (odds ratio 2.1; 95% confidence interval 1.7, 2.4). After adjusting for other significant factors, African-American race retained the strongest association with recurrent spontaneous preterm birth<34 weeks. Within each racial group, short cervical length<25mm before 27 weeks' gestation had the highest hazard of recurrent spontaneous preterm delivery. ConclusionDespite treatment with 17P, African-American women have higher rates of recurrent preterm birth.
引用
收藏
页码:55 / 60
页数:6
相关论文
共 50 条
  • [41] A randomized trial of 17-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV
    Price, Joan T.
    Vwalika, Bellington
    Freeman, Bethany L.
    Saha, Pooja T.
    Cole, Stephen R.
    Mbewe, Felistas
    Phiri, Winifreda M.
    Peterson, Marc
    Muyangwa, Dorothy
    Sindano, Ntazana
    Mwape, Humphrey
    Smithmyer, Megan E.
    Kasaro, Margaret P.
    Mofenson, Lynne M.
    Rouse, Dwight J.
    Goldenberg, Robert L.
    Chomba, Elwyn
    Stringer, Jeffrey
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2021, 224 (02) : S6 - S7
  • [42] Reassessing Preterm Birth Prevention After the Withdrawal of 17-α Hydroxyprogesterone Caproate
    Heyborne, Kent D.
    OBSTETRICS AND GYNECOLOGY, 2023, 142 (03): : 493 - 501
  • [43] 17 α-Hydroxyprogesterone Caproate (Makena®)A Guide to Its Use in the Prevention of Preterm Birth
    Mary Hines
    Katherine A. Lyseng-Williamson
    Emma D. Deeks
    Clinical Drug Investigation, 2013, 33 : 223 - 227
  • [44] Metabolism of 17α-Hydroxyprogesterone Caproate, an Agent for Preventing Preterm Birth, by Fetal Hepatocytes
    Sharma, Shringi
    Ellis, Ewa C. S.
    Dorko, Kenneth
    Zhang, Shimin
    Mattison, Donald R.
    Caritis, Steve N.
    Venkataramanan, Raman
    Strom, Stephen C.
    DRUG METABOLISM AND DISPOSITION, 2010, 38 (05) : 723 - 727
  • [45] Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth
    Edwards, Alexandra M.
    Lowry, Sarah A.
    Mikovich, Sam
    Forinash, Alicia B.
    Babbar, Shilpa
    AMERICAN JOURNAL OF OBSTETRICS & GYNECOLOGY MFM, 2020, 2 (03)
  • [46] Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention
    Manuck, Tracy A.
    Watkins, W. Scott
    Moore, Barry
    Esplin, M. Sean
    Varner, Michael W.
    Jackson, G. Marc
    Yandell, Mark
    Jorde, Lynn
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2014, 210 (04) : 321.e1 - 321.e21
  • [47] The Effectiveness of 17α-Hydroxyprogesterone Caproate in Obese Women for Prevention of Preterm Delivery
    Ngai, Ivan
    Marji, Melissa
    Neto, Nicole
    Garretto, Diana
    Sheen, Jean-Ju
    Garry, David J.
    OBSTETRICS AND GYNECOLOGY, 2014, 123 : 161S - 162S
  • [48] Effect of obesity on efficacy of 17 hydroxyprogesterone caproate in preventing recurrent preterm birth
    Stout, Molly J.
    Odibo, Anthony O.
    Macones, George A.
    Cahill, Alison G.
    Fowler, Susan A.
    Tuuli, Methodius G.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2017, 216 (01) : S348 - S349
  • [49] 17 α-Hydroxyprogesterone Caproate (Makena®) A Guide to Its Use in the Prevention of Preterm Birth
    Hines, Mary
    Lyseng-Williamson, Katherine A.
    Deeks, Emma D.
    CLINICAL DRUG INVESTIGATION, 2013, 33 (03) : 223 - 227
  • [50] Understanding barriers to uptake of 17 alpha-hydroxyprogesterone caproate (17-OHP) in women with history of preterm birth
    Kalata, Megan
    Teter, Kellie
    Wagner, Lisa
    Swarr, Vicki
    Witzeman, Kathryn
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2021, 34 (04): : 541 - 546